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Abstract
Background: There are various methods for detecting sentinel lymph nodes in breast cancer. Sentinel lymph node
biopsy (SLNB) using a vital dye is a convenient and safe, intraoperatively preparative method to assess lymph node
status. However, the disadvantage of the dye method is that the success rate of sentinel lymph node detection
depend on the surgeon’s skills and preoperative mapping of the sentinel lymph node is not feasible. Currently, a
vital dye, radioisotope, or a combination of both is used to detect sentinel nodes. Many surgeons have reported
successful results using either method. In this study we have analyzed breast lymphatic drainage pathways using
indocyanine green (ICG) fluorescence imaging.
Methods: We examined the lymphatic courses, or lymphatic vessels, in the breast using ICG fluorescence imaging,
and applied this method to SLNB in patients who underwent their first operative treatment for breast cancer
between May 2006 and April 2008. Fluorescence images were obtained using a charge coupled device camera
with a cut filter used as a detector, and light emitting diodes at 760 nm as a light source. When ICG was injected
into the subareola and periareola, subcutaneous lymphatic vessels from the areola to the axilla became visible by
fluorescence within a few minutes. The sentinel lymph node was then dissected with the help of fluorescence
imaging navigation.
Results: The detection rate of sentinel nodes was 100%. 0 to 4 states of lymphatic drainage pathways from the
areola were observed. The number of sentinel nodes was 3.41 on average.
Conclusions: This method using indocyanine green (ICG) fluorescence imaging may possibly improve the
detection rate of sentinel lymph nodes with high sensitivity and compensates for the deficiencies of other
methods. The ICG fluorescence imaging technique enables observation of breast lymph vessels running in multiple
directions and easily and accurately identification of sentinel lymph nodes. Thus, this technique can be considered
useful.
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Background
Sentinel lymph node biopsy (SLNB) is useful to predicts
accurate pathological nodal staging and detect the exis-
tence of axillary lymph node metastasis. The major pro-
blem of axillary dissection is that it produces various
morbidities such as serome, infection, numbness and
lymphadema of the arm [1,2]. Since April 2010, this
technique has been covered by the national health
insurance in Japan, promoting its wide use in clinical
settings. False-negative of SLNB is a critical problem, as
it may lead to inadequate adjuvant therapy, which can
negatively affect a patient’s prognosis. Currently, three
methods are available to identify sentinel lymph nodes:
the dye method, the gamma probe method, and a com-
bination of both [3-14]. Although the dye method has
several benefits including ease of use, cost effectiveness
and safety, it has been pointed out that the detection
rate is low compared to the gamma probe method
[3-14]. The avoidance of radioisotope is also beneficial
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especially at institutes where the use of radioisotope is
limited. Reports have indicated that the percentage of
false-negative SLNB results could be less than 5% in
experienced hands if dual-agent techniques are used
[3-16]. Meanwhile, the lymphoscintigraphy with a radio-
isotope cannot clearly visualize the lymphatic drainage
pathway. The photodynamic eye (PDE) can visualize the
lymphatic drainage pathway clearly and demonstrate the
accurate location of sentinel lymph node real-time in
the operating room. In our study, we performed SLNB
using the indocyanine green (ICG) fluorescence techni-
que to determine whether this can overcome the short-
comings of the dye method, and analyzed breast
lymphatic drainage pathways.
Methods
Sample collection
Of the 414 patients who underwent their first operative
treatment for primary breast cancer between May 2006
and April 2008, 312 patients who were clinically negative
for lymph node metastasis were enrolled in this study. A
total of 102 patients underwent axillary dissection. Patients
whose intraoperative histological results were negative for
malignancy underwent no further axillary dissection,
whereas the following patients continued to complete axil-
lary dissection: (1) patients with clinically apparent positive
nodes (102 cases); (2) patients with positive intraoperative
frozen section diagnosis (49 cases,). If the node contained
a metastasis, complete axillary dissection was performed
immediately (49 cases, 15%).
All patients were informed of the aims of the study,
the potential effects of the procedures, the risks asso-
ciated with surgery, and purpose of randomization. All
patients signed a written consent form approved by the
institutional ethics committee (institutional review
board) of Tokyo Women’s Medical University before the
operation.
Operative procedure
SLNB was performed before wide excision, breast con-
serving surgery, or mastectomy as follows.
1) 5 ml of 20 times diluted indocyanine green (ICG)
(Diagnogreen 0.5%; Daiichi Pharmaceutical, Tokyo,
Japan) is injected into the subareola and periareola. (20
times dilution: ICG is dissolved in 10 ml of solution to be
diluted 20 times, i.e., a concentration of 0.125 mg/ml).
2) Breast massage is performed for 10-20 seconds.
(ICG is combined with serum proteins and moved into
the lymph vessels. Massaging the injected area will
increase the interstitial pressure of tissues [17-19],
which in turn facilitates the absorption of ICG into the
lymph vessels.) Following a few seconds of massage,
subcutaneous lymphatic drainage pathway was then
observed with fluorescence image (Figure 1, 2).
3) After the surgical lights are turned off, image acqui-
sition is started using the Photodynamic Eye (PDE)
infrared camera system manufactured by Hamamatsu
Photonics K.K., while infrared light of 760 nm wave-
length is being emitted under room fluorescent lighting.
(The principle of fluorescence measurement is as fol-
lows: Injected ICG molecules are promptly bound to the
globulin fractions in serum proteins. Under this condi-
tion, when excitation light of 760 nm is irradiated, fluor-
escence with a peak wavelength of 845 nm will be
emitted. This process is captured by a CCD camera with
sensitivity in the near-infrared wavelength range).
4) The fluorescence emitted by ICG is followed in the
direction from the areola toward the axilla, and a mark-
ing is made on the skin where the fluorescence disap-
pears (Figure 1, 2, 3).
5) Skin incision is made at that position and the sub-
dermal layer is removed. Observation by fluorescence
imaging is performed again. If there is any site that
emits a strong fluorescence, that site is removed along
with the surrounding tissue (Figure 3).
6) Lymph nodes in the dissected specimen are isolated
from surrounding fatty tissue, and investigated to see
nipple
nipple
axilla
axilla
Figure 1 Two patterns of lympathic drainage pathways from
the breast to the axillary basin were found. (1) One pattern was
a subcutaneous lymphatic vessel from the subareolar area running
through the anterior surface of the breast into the lymph node in
the midaxilla near the intercostals brachial nerve. Patterns of
subcutaneous lymphatic drainage pathway from the areola into the
axilla: From one to two streams was drained.
axilla
axilla
nipple
nipple
lymph node
Figure 2 (2) Another pattern was a lymphatic a lymphatic
vessel running directly from the lateral edge of the
parenchyma and through the posterior surface of the breast
into the lower axilla, and then to the lymph node located at
the midaxilla. Several lymphatic drainage pathways from the
areolar area were observed. Several streams from the areola joined
together before they drained to the axilla.
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whether each lymph node is fluorescent inside. All
fluorescent lymph nodes are regarded as sentinel nodes.
Anatomical localization of sentinel lymph nodes is
recorded according to Berg’s level classification. Obser-
vation is made again to see if any fluorescence is present
on and around the removed lymph nodes (Figure 3).
7) The extracted sentinel lymph nodes are checked for
metastasis by intraoperative biopsy with frozen section.
Finally, permanent pathological diagnosis is conducted
by postoperative HE staining.
All sentinel lymph node positivity were determined
intraoperatively by frozen-tissue examination and con-
firmed postoperatively in formalin-fixed, paraffin-
embedded tissue sections stained with hematoxylin and
eosin. We did not use immunohistochemistry. Each sen-
tinel lymph node was evaluated at 1 level for nodes of 1
cm or less and at 3 separate levels for nodes of more
than 1 cm. Patients given diagnoses of positive sentinel
lymph nodes based on frozen-section diagnosis immedi-
ately underwent an axillary lymph node dissection of
level Ⅰ Ⅱ.
Statistical analysis
Fisher’s exact test was used to evaluate the significance
of any relationship between the clinicopathological fea-
tures and the success of SLNB in identifying sentinel
nodes. Differences were considered to be significant
when p < 0.05.
Results
Identification rate: 100%
The average age was 57.4 years old. Of the 312 patients,
214 had a tumor of less than 2 cm in diameter and 98,
a tumor of 2 cm or more, with 95 having had mastect-
omy and 217 partial mastectomy (Table 1). Non-invasive
tumor was found in 47 patients, invasive tumor in 265,
Fig 3-c
Fig 3-bFig 3-a
Figure 3 It is possible to see the fluorescent lymph vessels that run from the body surface to the axilla. Figure 3-a: A skin incision is
made at the end of fluorescence emission that extends to the axilla, in order to observe the fluorescent lymph vessels embedded in the
subcutaneous tissue. The fluorescent lymph nodes at the end of the lymph vessels are identified. Figure 3-b: After skin incision, the
subcutaneous lymphatics were more clearly visible by fluorescence. Figure 3-c: The lymphatic channels and nodes that received ICG appeared as
shining fluorescent streams and spots in the fluorescence image. The lymph node was dissected along with its surrounding fatty tissue.
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and vascular invasion in 152 (Table 2). Hormonal recep-
tor status was positive in 159 patients (50.9%) and nega-
tive in 72 (23%). HER-2 status was positive in 46
patients (14.7%) (Table 3).
We observed two main lymphatic drainage pathways
draining from the areola in the direction of the axilla: one
was directly toward the axilla and the other was toward
and through the outside of the mammary gland (Figures 1
and 2). When lymphatic drainage pathway or sentinel
lymph nodes were not clearly visible in green color, fluor-
escence imaging was used for directional guidance. The
lymphatic flow through the mammary gland was primarily
directed to the axillary lymph nodes, and the flow toward
the parasternal lymph nodes or the supraclavicular lymph
nodes was not observed in our study.
The number of the lymphatic vessels ranged from one
to four, with the average number of identified sentinel
lymph nodes being 3.41 (Table 4). (In addition to the
fluorescent lymph nodes, the swelling lymph nodes
detected by palpation were also sent to intraoperative
biopsy as Level I.)
Patients whose intraoperative histological results were
negative for malignancy underwent no further axillary
dissection, whereas the following patients continued to
complete axillary dissection: (1) patients with clinically
apparent positive nodes (102 cases); (2) patients with
positive operative frozen section diagnosis (49 cases).
When the presence of lymph node metastasis was
observed in intraoperative biopsy, a total dissection of
the axillary lymph nodes was performed (49 patients,
15%). There were 8 patients in whom metastatic lesions
were not found in the identified lymph nodes by intrao-
perative biopsy but metastasis was detected in permanent
preparation at a later date. These were false negative
cases, resulted from the fact that metastatic lesions in the
slice for intraoperative biopsy were too small and it was
only possible to detect such lesions using permanent pre-
paration. Any metastatic lesion in the 8 patients who
showed false negative results for metastasis was very
small, less than 2 mm, which prevented detection by
intraoperative biopsy. Side effects such as intraoperative
allergy due to ICG were not observed.
Of the 263 patients who showed negative results for sen-
tinel lymph node metastasis, 6 patients developed post-
operative distant metastasis (supraclavicular lymph nodes
in one patient, subpectoral lymph nodes in one, lung in
two, brain in one and liver in one). Of the 49 patients in
which the presence of sentinel lymph node metastasis was
observed by intraoperative biopsy and a total dissection of
the axillary lymph nodes was performed, 4 patients devel-
oped postoperative distant metastasis (parasternal lymph
nodes in one patient, lung in one, bone in one and brain
in one) (Table 5). None of the patients in this study suf-
fered disease relapse in axillary lymph nodes during a
median follow-up period of 49 months.
Of the patients who received sentinel lymph node
biopsy, 1 developed metastasis in the remaining breast
after breast conserving surgery. In those who tested
negative for metastasis by SLNB, no patient developed
metastasis in the axillary lymph nodes (Table 5).
Discussion
Many studies have been conducted on SLNB, since the
publication by Krag et al. on the method using
Table 1 Characteristics of patients and tumors
Age: 57.4 (29-85)
Diameter of tumor < 2.0 cm 214(69%)
> 2.1 cm 98(31%)
Site of tumor Upper inner A 57 (18%)
Lower inner B 24 (8%)
Upper outer C 133 (43%)
Lower outer D 22 (7%)
Central E 76 (24%)
Operative procedure Conservation 95 (30%)
Mastectomy 217 (70%)
Table 2 Clinicopathological features
Histological type
A
Ductal infiltrating
Intraductal carcinoma 47 (15%)
Invasive ductal carcinoma 239 (77%)
B
Lobular infiltrating
13 (4%)
C
Other
13 (4%)
Peritumoral vascular invasion
(lymphatic or vascular invasion)
Positive 152 (49%)
Negative 160 (51%)
Table 3 Tumor characteristics
Hormonal receptor status ER (+) and PR (+) 159 (51%)
ER (+/-)and/or PR(+/-) 81 (26%)
ER (-) and PR (-) 72 (23%)
HER2 status 0 168 (54%)
1+ 74 (24%)
2+ 24 (7%)
3+ 46 (15%)
Tumor grade I 219 (70%)
II 80 (26%)
III 13 (4%)
ER: Estrogen receptor
PR: Progesterone receptor
HER2: Human epidermal growth receptor 2
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radioisotope in 1993 [10,11], and a report by Giuliano et
al. on the dye method in 1994 [12,13]. Veronesi et al
suggested the possibility that a total dissection of the
axillary lymph nodes is not always necessary, and a large
scale RCT was carried out [1,2,20-29]. These reported
successful lymphatic mapping in 92% using a combina-
tion of a dye and a gamma probe method. They found
that SLNB using dye alone allowed the identification in
approximately 70-80% of patients and that adding a
radioisotope improved the detection rate. It is therefore
certain that the combination of dye and radioisotope
will become more commonly used in SLNB [3-16].
It is important, therefore, that the accuracy of SLNB
be secured by each surgeon and each institute.
Currently, two types of tracers, dye and radioisotope,
are used to detect the sentinel lymph nodes in breast
cancer patients, and a combined use of the two tracers
has yielded a high diagnostic value [3-14].
We performed the SLNB using the ICG fluorescence
measurement technique in order to overcome some
drawbacks inherent in the dye method (Table 6). At our
department, the identification rate of sentinel lymph
nodes is 100%. This is a result similar to or better than
those reported by other researchers, which were
obtained by the gamma probe method or the combined
method that uses the gamma probe and the dye [3-14].
Thus, it can be said that SLNB using ICG fluorescence
could be very useful.
We usually inject ICG into the subareola and periar-
eola. Because the mammary gland is embryologically
derived from the ectoderm, it is thought that the mam-
mary gland tissue and the subcutaneous tissue share
common lymphatic vessels, which lead to the relevant
lymph nodes [30-34]. Lymphatic flow originating in the
mammary gland tissues first moves into the subareolar
lymphatic vessels, and then drains to the axillary lymph
nodes. Therefore, the injection of ICG into the subar-
eola and periareola allows us to identify the same senti-
nel lymph nodes as those identified with the
peritumonal injection. Some studies [30-34] attempted
to clarify whether injection of mapping agents into the
subareolar breast tissue results in the identification of
the same sentinel lymph nodes as injection into intra-
dermal sites overlying the breast tumor. It would be
simpler if the injection could be performed in the same
manner for all patients regardless of tumor location or
palpability. Other studies [30-34] have shown that a der-
mal or subdermal injection of mapping agents results in
more reliable sentinel lymph node identification than a
peritumonal injection. It has been hypothesized that the
lymphatic drainage pathway of the entire breast flows to
the same few sentinel lymph nodes. No lymphatic
Table 4 Number of lymphatic flows and nodes
Direction of lymph current
(1) Toward the axilla
(2) Toward and through the outside of the mammary gland
Number of lymph currents and proportion (%) 0 2%
1 35%
2 46%
3 12%
4 5%
Identification rate: 100%
Identified lymph nodes (average) Sentinel lymph nodes 3.41 (range: 1-12)
Level I 1.66 (range: 0-10)
Total 5.07 (range: 1-17)
Table 5 Unfavorable events and deaths
SLNB Group (n =
263)
SLNB- > ALND
Group (n =
49)
Unfavorable events 0 0
Events other than death 0 0
Axillary metastasis 0 0
Supraclavicular metastasis 1 (0.3%) 0
Recurrence in ipsilateral
breast
18 (0.3%) 0
Cancer in contralateral breast 0 0
Distant metastasis 5 (2%) 4 (8%)
Other primary tumor 0 0
Death due to breast cancer 3 (1%) 2 (4%)
Death from other causes 0 0
ALND: Axillary lymph node dissection
SLNB: Sentinel lymph node biopsy
SLNB- > ALND: Because of being positive for lymph node metastasis in
sentinel lymph biopsy, a total dissection of the axillary lymph nodes was
applied.
Statistical significance was evaluated using the chi-square test or Fisher’s
exact probability test. There were no significant differences between the two
groups. (P = 0.55)
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drainage pathway was observed to the parasternal lymph
node and the supraclavicular lymph node. It was
reported that the lymphatic drainage pathway in the
breast parenchyma flowed toward the subareolar lym-
phatic plexus and drained in to the axilla [30-34]. In the
present study, a lymphatic drainage pathway from the
areolar area was detected in almost all patients.
In our study, ICG, which was injected into the subar-
eola and periareola, emitted a high level of fluorescence
at the injection location, then promptly moved into the
lymphatic vessels, and finally spread further through the
lymphatic flow courses. The PDE infrared camera sys-
tem has an ability to capture fluorescence up to a depth
of 1 cm from the skin surface. In patients with a low
body mass index (BMI), it was possible to directly
observe the fluorescent lymph nodes in the axillary
region because their subcutaneous fat layer was thin.
On the other hand, patients with a high BMI usually
have a thick subcutaneous fat layer, making it difficult
or impossible to track the lymphatic drainage pathway
toward the axilla by fluorescence. It seems that in 7
patients (2%) failure to detect a lymphatic drainage
pathway was unavoidable, as all 7 patients were obese
(BMI > 30). BMI has been shown to correlate with an
increased incidence of failure in identifying a sentinel
lymph node. The specific causes of mapping failure
remain uncertain, but some contributing factors have
been observed [35-39]. Using inadequate volume of
injection, inadequate dispersion, inappropriate timing,
and inadequate massage may weaken the ability of the
dyes and radioisotopes to reach the nodal basin. Fatty
tissue around the lymph nodes may also cause decreased
flow to the lymphatic basin. Successfully lymphatic drai-
nage pathway mapped patients had a mean BMI of 22.3
kg/m2 (range 17.9 to 33 kg/m2).
However, for these obesity patients (BMI > 30), it was
possible to easily identify the lymph nodes and lympha-
tic vessels embedded in the adipose tissue by incising
the subcutaneous fat in the axillary incision site. The
intensity of fluorescence can be adjusted if required. It
is also possible to distinguish between the fluorescence
from the lymph nodes or lymphatic vessels and the
fluorescence from ICG that happens to attach some-
where. If the fluorescence is strong, and can determine
whether the lymph nodes or lymphatic vessels, the
deposit of a ICG is also possible to adjust the high and
low emission intensity of the device. None of these obe-
sity 7 patients were not failed to identify sentinel lymph
node and not had false negative sentinel lymph nodes.
More sentinel lymph nodes were detected by ICG
fluorescence imaging compared with other methods
(Table 4) [1-14,17,18]. The uptake of the localization
agents into the lymphatic vessels is dependent on the
interstitial pressure [19,30-39]. Our data from past
experiences suggest that ICG fluorescence could detect
a wide range of sentinel lymph nodes. ICG in the lymph
node can be illuminated by fluorescence with very high
sensitivity even if it does not appear green. When we
detect many harvested sentinel lymph nodes, the follow-
ing can be suggested according to several differences
between the dye and radioisotope: (1) the molecular
weight and the chemical structure, (2) the intensity of
binding of some kinds of protein to the tracers, (3) the
injection time to tracers, and (4) the sensitivity of meth-
ods [3,4]. The small blue dye crystals passively rely on
prevailing fluid dynamics for visualization of the lymph
node as fluorescence is emitted. Our experiments clearly
revealed that extensive sentinel lymph nodes in the
axilla could be detected only with the ICG fluorescence
method. In our department, 20 times diluted ICG is
used. The intensity level of fluorescence obtained from
this ICG is appropriate, allowing us to perform the
SLNB in an effective and efficient manner. It was possi-
ble to identify the irregularities, which may appear
around the fluorescence emission when some lymphatic
vessels are damaged, by adjusting the emission intensity
of fluorescence. It is also possible to distinguish the
lymph node from the lymphatic vessel by adjusting the
fluorescence emission intensity. (The lymph nodes illu-
minate in a spotty pattern, whereas the lymph vessels
illuminate in a linear or streaky pattern.)
We observed two main lymphatic drainage pathways
draining from the areola in the direction of the axilla:
one was directly toward the axilla and the other was
Table 6 Benefits and Drawbacks of ICG Flourescence Method
Benefits of ICG fluorescence method Drawbacks of ICG fluorescence method
(1) The subcutaneous lymphatic vessels running from the areola to the
axilla can be observed from outside, through the skin allowing of the
accurate determination location of the skin incision in the axilla.
(1) If lymph vessels that have been emitting fluorescence signal are
damaged, ICG will leak into the surrounding tissue, preventing an
accurate identification of sentinel lymph nodes.
(2) Fluorescence can be used as a guide to remove the lymph vessels
running toward the axilla more easily.
(2) Many lymph nodes that are emitting fluorescence, with an average of
five or more, can appear
(3) If any fluorescence signal is detected in the extracted lymph nodes, it
means there are sentinel lymph nodes in those lymph nodes.
(3) Skin pigmentation due to ICG remains for a certain period of time.
(4) Other benefits include: no exposure to radiation, easy to use, and
cost effectiveness.
Aoyama et al. World Journal of Surgical Oncology 2011, 9:157
http://www.wjso.com/content/9/1/157
Page 6 of 8
toward and through the outside of the mammary gland.
Regarding the number of lymphatic vessels, it was
observed in many patients that several lymphatic vessels
running in the same direction join together to form the
lymphatic vessel network. In some cases, it flows into
multiple sentinel lymph nodes through multiple lympha-
tic vessels (Figure 1, 2).
When the presence of lymph node metastasis was
observed in intraoperative biopsy, a total dissection of
the axillary lymph nodes was performed. However, addi-
tional surgery is not usually performed for patients in
which micrometastasis is detected by the postoperative
HE staining of permanent preparation but other lymph
nodes removed as part of a group sentinel are metasta-
sis-negative. Currently, postoperative tumor recurrence
in the axillary lymph nodes has not been observed
(Table 5). The clinical significance of micrometastasis
and ITC (isolated tumor cell) has not been established.
These were false negative cases, resulting from the fact
that metastatic lesions in the slice for intraoperative
biopsy were too small and it was only possible to detect
such lesions using permanent preparation. Any meta-
static legion in the 8 patients who showed false negative
results for metastasis was very small, less than 2 mm,
which prevented detection by intraoperative biopsy.
However, some reports have suggested that there might
be an association between micrometastasies in the
lymph nodes and distant metastasis [27-29]. The prog-
nostic significance of a micrometastasis in terms of
metastatic risk is controversial [1,2,20-29].
At present, no standard guidelines are available for
dealing with micrometastasies in the sentinel lymph
nodes. Among the patients who underwent a total dis-
section because metastasis had been detected in a single
sentinel lymph node, no patient developed metastasis in
other organs or parts other than the sentinel lymph
nodes. If we are able to accurately identify the patients
with metastasis only in the sentinel lymph node(s), it
would be possible to reduce the need for further surgery
or unnecessary total dissections.
Conclusions
The fluorescence method allows us to see how the lym-
phatic drainage pathway flows from the areola toward
other parts in real-time during surgery, as well as clearly
understand how the lymphatic vessels run from the are-
ola to the axilla. With the dye method, sometimes it is
difficult or impossible to visually determine whether the
extracted lymph nodes are sentinel lymph nodes or not.
Meanwhile, with the fluorescence method, this can be
done relatively easily by checking the existence of fluor-
escence in the extracted lymph nodes. This method is a
technique that enables us to easily identify the sentinel
lymph nodes during surgery with low invasiveness and
no exposure to radiation, thus providing a safe and very
useful way to detect the axillary sentinel lymph nodes in
patients with breast cancer, in additon to improving the
identification rate.
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